Open AccessPhase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies
Author(s) -
Amit Mahipal,
Dave Shibata,
Erin M. Siegel,
Gregory M. Springett,
Khaldoun Almhanna,
William J. Fulp,
Irene Williams-Elson,
Richard D. Kim
Publication year - 2015
Publication title -
investigational new drugs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 87
eISSN - 1573-0646
pISSN - 0167-6997
DOI - 10.1007/s10637-015-0277-8
Subject(s) - pasireotide , medicine , folfiri , gastroenterology , tolerability , irinotecan , adverse effect , regimen , oncology , phases of clinical research , combination therapy , colorectal cancer , chemotherapy , pharmacology , cancer , acromegaly , hormone , growth hormone
Pasireotide (SOM230) is a somatostatin analog with high binding affinity for somatostatin receptors including sst1, 2, 3 and 5 and inhibit insulin like growth factor-1. Blocking of IGF-1 receptor (IGF-1R) in combination with cytotoxic chemotherapy has demonstrated additive or synergistic activity in pre-clinical models. This study aimed to evaluate the maximum tolerated dose (MTD) of pasireotide in combination with standard FOLFIRI (5-fluorouracil, leucovorin and irinotecan) regimen in patients with gastrointestinal malignancies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom